🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,762 results for “CTI” Clear

  1. Zelvina 5 mg hard capsules, Dexamethasone Tablets BP 2.0mg, Fortecortin® 2 mg Tabletten, Revlimid 25 mg hard capsules, Zelvina 10 mg hard capsules, Revlimid 5 mg hard capsules, Dexamethason 8 mg GALEN® Tabletten, Revlimid 10 mg hard capsules, Dexamethason 8 mg JENAPHARM®, Zelvina 25 mg hard capsules, DARZALEX 1800 mg solution for injection

    GlaxoSmithKline

    Multiple myeloma

    phase 3 small molecule active

    1 trial

  2. Zeposia 0.23 mg hard capsules Zeposia 0.46 mg hard capsules, Zeposia 0.23 mg hard capsules Zeposia 0.46 mg hard capsules, Zeposia 0.92 mg hard capsules

    Celgene Europe Limited

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  3. Zilbrysq 23 mg solution for injection in pre-filled syringe, Zilucoplan sodium, -, Zilbrysq 16.6 mg solution for injection in pre-filled syringe, Zilbrysq 32.4 mg solution for injection in pre-filled syringe

    Lacuna Pharma Pty Ltd

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  4. Zilbrysq 32.4 mg solution for injection in pre-filled syringe, Zilbrysq 23 mg solution for injection in pre-filled syringe, Zilbrysq 16.6 mg solution for injection in pre-filled syringe

    Lacuna Pharma Pty Ltd

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  5. Zilbrysq 32.4 mg solution for injection in pre-filled syringe, Zilbrysq 23 mg solution for injection in pre-filled syringe, Zilucoplan sodium, -, Zilbrysq 16.6 mg solution for injection in pre-filled syringe

    Lacuna Pharma Pty Ltd

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  6. Zipalertinib Placebo Tablets is a film-coated tablet that does not contain the active ingredient, zipalertinib., Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Zipalertinib, Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Taiho Pharma Netherlands B.V.

    Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations

    phase 3 small molecule active

    1 trial

  7. Zolpidem extended-release

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Addiction

    phase 3 small molecule completed

    1 trial

  8. Zometa 4 mg/100 ml solution for infusion, XGEVA 120 mg solution for injection in pre-filled syringe

    CERO THERAPEUTICS HOLDINGS, INC.

    Patients, men or women over 18 old, with inoperable vertebral bone metastases who must beneficit treatment with stereotactic radiotherapy

    phase 3 small molecule active

    1 trial

  9. [18F]-AlF-FAPI-74, GlucaGen®, HypoKit met 1 mg poeder en oplosmiddel voor oplossing voor injectie, Scopolamine butylbromide Kalceks 20 mg/ml oplossing voor injectie

    Disc Medicine

    Cholangiocarcinoma

    phase 3 small molecule active

    1 trial

  10. abamectin and fenpyroximate

    United Therapeutics Europe Ltd

    Malaria

    phase 3 small molecule terminated

    1 trial

  11. alprazolam, Placebo matching Staccato® alprazolam and without active substance

    Lacuna Pharma Pty Ltd

    Treatment of stereotypical prolonged seizure

    phase 3 small molecule active

    1 trial

  12. balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg

    AstraZeneca

    Heart Failure and Impaired Kidney Function

    phase 3 small molecule active

    1 trial

  13. belapectin

    GALECTIN THERAPEUTICS INC

    Prevention of Esophageal Varices

    phase 3 small molecule terminated

    1 trial

  14. bimekizumab

    Lacuna Pharma Pty Ltd

    Active juvenile idiopathic arthritis subtypes enthesitis-related arthritis (including juvenile-onset ankylosing spondylitis) and juvenile psoriatic arthritis

    phase 3 small molecule active

    1 trial

  15. bimekizumab, Skyrizi 150 mg solution for injection in pre-filled syringe, Placebo matching test and comparator. 0.9% sodium chloride solution for injection (unauthorized).

    Lacuna Pharma Pty Ltd

    Psoriatic arthritis

    phase 3 small molecule active

    1 trial

  16. bivalent enterovirus vaccine (Vero cell), inactivated

    Sinovac Research and Development Co.,

    Hand, Foot, and Mouth Disease（HFMD)

    phase 3 mab active

    1 trial

  17. brivaracetam, -, -, brivaracetam, -, brivaracetam, Placebo matching < brivaracetam oral solution> and without active substance

    Lacuna Pharma Pty Ltd

    Childhood Absence Epilepsy Juvenile Absence Epilepsy

    phase 3 small molecule active

    1 trial

  18. cART(TDF/AZT+3TC+LPV/r)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute HIV Infection

    phase 3 small molecule active

    1 trial

  19. centrally blinded product containing all the same manufactured ingredients and excipients as the DM199 formulation, except for the active pharmaceutical ingredient (API).

    DiaMedica Therapeutics

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

  20. dactinomycin

    Solid Biosciences

    Sarcoma

    phase 3 mab active

    1 trial

  21. dactinomycin

    Children's Hospital of Fudan University

    Kidney Cancer

    phase 3 mab completed

    1 trial

  22. decitabine

    The First People's Hospital of Lianyungang

    Poor Graft Function

    phase 3 small molecule active

    1 trial

  23. deucravacitinib, Placebo to match deucravacitinib tablet

    Bristol-Myers Squibb Australia Pty Ltd

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  24. different degrees of adjustment of the injection interval

    The First People's Hospital of Lianyungang

    Exudative Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources